TY - JOUR
T1 - Immune milieu established by postpartum liver involution promotes breast cancer liver metastasis
AU - Bartlett, Alexandra Q.
AU - Pennock, Nathan D.
AU - Klug, Alex
AU - Schedin, Pepper
N1 - Funding Information:
Funding: This research was funded by the following grants to PS: Department of Defense grant #BC170206, Department of Defense grant #BC191620, Eccles Foundation, and funds from the Knight Cancer Institute (KCI). This work was also supported by the KCI Cancer Center Support Grant P30CA69533. AQB was partially supported by the following: Ruth L Kirschstein T32 “PERT” Training Grant, Achievement Rewards for College Scientists (ARCS) Foundation, and the OHSU Cancer Biology Graduate Program Student Stipend Award.
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/4/1
Y1 - 2021/4/1
N2 - In rodents, we identified a physiologic process within the normal liver that creates a pre-metastatic niche. This physiology is weaning-induced liver involution, characterized by hepatocyte cell death, immune influx, and extracellular matrix remodeling. Here, using weaning-induced liver involution as a model of a physiologically regulated pro-metastatic niche, we investigate how liver involution supports breast cancer metastasis. Liver metastases were induced in BALB/c immune competent hosts by portal vein injection of D2OR (low metastatic) or D2A1 (high metastatic) mouse mammary tumor cells. Tumor incidence and multiplicity increased in involution hosts with no evidence of a proliferation advantage. D2OR tumor cell extravasation, seeding, and early survival were not enhanced in the involuting group compared to the nulliparous group. Rather, the involution metastatic advantage was observed at 14 days post tumor cell injection. This metastatic advantage associated with induction of immune tolerance in the involution host liver, reproductive state dependent intra-tumoral immune composition, and CD8-dependent suppression of metastases in nulliparous hosts. Our findings suggest that the normal postpartum liver is in an immune suppressed state, which can provide a pro-metastatic advantage to circulating breast cancer cells. Potential relevance to women is suggested as a postpartum diagnosis of breast cancer is an independent predictor of liver metastasis.
AB - In rodents, we identified a physiologic process within the normal liver that creates a pre-metastatic niche. This physiology is weaning-induced liver involution, characterized by hepatocyte cell death, immune influx, and extracellular matrix remodeling. Here, using weaning-induced liver involution as a model of a physiologically regulated pro-metastatic niche, we investigate how liver involution supports breast cancer metastasis. Liver metastases were induced in BALB/c immune competent hosts by portal vein injection of D2OR (low metastatic) or D2A1 (high metastatic) mouse mammary tumor cells. Tumor incidence and multiplicity increased in involution hosts with no evidence of a proliferation advantage. D2OR tumor cell extravasation, seeding, and early survival were not enhanced in the involuting group compared to the nulliparous group. Rather, the involution metastatic advantage was observed at 14 days post tumor cell injection. This metastatic advantage associated with induction of immune tolerance in the involution host liver, reproductive state dependent intra-tumoral immune composition, and CD8-dependent suppression of metastases in nulliparous hosts. Our findings suggest that the normal postpartum liver is in an immune suppressed state, which can provide a pro-metastatic advantage to circulating breast cancer cells. Potential relevance to women is suggested as a postpartum diagnosis of breast cancer is an independent predictor of liver metastasis.
KW - Breast cancer
KW - Liver involution
KW - Liver metastasis
KW - Metastatic niche
UR - http://www.scopus.com/inward/record.url?scp=85103485331&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103485331&partnerID=8YFLogxK
U2 - 10.3390/cancers13071698
DO - 10.3390/cancers13071698
M3 - Article
AN - SCOPUS:85103485331
SN - 2072-6694
VL - 13
JO - Cancers
JF - Cancers
IS - 7
M1 - 1698
ER -